PARP1 and breast cancer: Here, we show, for the first time, that SOC therapies used in ER+ breast cancer (here: tamoxifen, fulvestrant and palbociclib) induce DNA damage along with inhibition of homologous recombination (HR) and toxic PARP1 trapping.